Alumis (ALMS) – Research Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Alumis (NASDAQ: ALMS):

• 8/23/2026 – Alumis was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 8/17/2026 – Alumis had its “neutral” rating reaffirmed by Citigroup Inc..
• 8/15/2026 – Alumis was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/14/2026 – Alumis had its “neutral” rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
• 8/3/2026 – Alumis had its “neutral” rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
• 7/7/2026 – Alumis had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Alumis

In other news, insider David M. Goldstein sold 2,596 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $68,456.52. Following the completion of the transaction, the insider directly owned 30,970 shares of the company’s stock, valued at approximately $816,678.90. This represents a 7.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Christopher Bradley sold 2,572 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $67,823.64. Following the sale, the insider owned 48,533 shares in the company, valued at $1,279,815.21. The trade was a 5.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 19,953 shares of company stock valued at $534,311 over the last ninety days. Insiders own 33.70% of the company’s stock.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.